Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model
Authors:
- 23 April 2007
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 118 (3) , 303-309
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Phase I Trial Evaluating the Safety of Bevacizumab With Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic CancerJournal of Clinical Oncology, 2006
- Enhancement of Anticancer Activity in Antineovascular Therapy Is Based on the Intratumoral Distribution of the Active Targeting Carrier for Anticancer DrugsBiological and Pharmaceutical Bulletin, 2006
- Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposomeJournal of Controlled Release, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugateBioorganic & Medicinal Chemistry Letters, 2004
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Anti-neovascular therapy using novel peptides homing to angiogenic vesselsOncogene, 2002
- Suppression of tumor growth by novel peptides homing to tumor‐derived new blood vesselsFEBS Letters, 2001
- Angiocytotoxic Therapy in Human Non-Small Cell Lung Cancer Cell Lines: Advantage of Combined Effects of TNP-470 and SN-38Acta Oncologica, 1998
- Inhibition of the metastatic spread and growth of B16‐BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitorInternational Journal of Cancer, 1994